Evaluation of Targeted Transcranial Direct Current Stimulation for Treating Refractory Status Epilepticus in Patients Aged 14 to 80

What this Trial Is About

Researchers are evaluating the safety and effectiveness of targeted transcranial direct current stimulation tDCS as a treatment for refractory status epilepticus, a severe type of seizure that does not respond to standard medications. This study compares real tDCS treatment to a sham inactive stimulation to better understand its potential benefits and risks. Participants are randomly assigned to either receive actual tDCS, where a 2 mA cathodal current is applied over the seizure onset zone for 20 minutes twice a day for several days up to 10 sessions, or to a sham group where the device is inactive but mimics the treatment schedule. Both groups follow the same timing and frequency of stimulation. During the study, participants will be monitored with EEG to assess seizure activity and determine if the status epilepticus ends. Researchers will track treatment-related side effects and compare outcomes between the two groups. The study lasts about one year on average, with ongoing evaluations until study completion.

Application of tDCS Stimulation in Controlling Refractory Status Epilepticus